Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Last trade$0.2436
Day change-$0.0244 (-9.10%)
Day range$0.239 – $0.291
Volume179,546
Market cap$15M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$14.85M
Price / earnings
—
Price / book
-18.36×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.7×
Profitability
Earnings per share
-$0.34
Return on assets
-573.73%
Return on equity
2,282.79%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0.5×
Current ratio
0.73×
Quick ratio
0.73×
Cash ratio
0.58×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$16.11M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ACTU, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$1.63M
$2.84M
$3.14M
$2.56M
$3.29M
$3.2M
$3.15M
$2.87M
Research and development
$1.81M
$2.07M
$2.57M
$2.13M
$2.18M
$2.76M
$3.22M
$3.69M
Total operating expenses
$3.44M
$4.91M
$5.71M
$4.69M
$5.47M
$5.97M
$6.37M
$6.56M
Operating income
-$3.44M
-$4.91M
-$5.71M
-$4.69M
-$5.47M
-$5.97M
-$6.37M
-$6.56M
Interest expense
-$5.06K
-$5.06K
-$5.06K
-$5.06K
-$5.06K
-$5.06K
-$5.06K
-$5.08K
Income before taxes
-$3.42M
-$4.87M
-$5.63M
-$4.55M
-$5.41M
-$5.95M
-$6.32M
-$6.45M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$3.42M
-$4.87M
-$5.63M
-$4.55M
-$5.41M
-$5.95M
-$6.32M
-$6.45M
Net income attributable to common shareholders
-$3.42M
-$4.87M
-$5.63M
-$4.55M
-$5.41M
-$5.95M
-$6.32M
-$6.45M
EBITDA
-$3.44M
-$4.91M
-$5.71M
-$4.69M
-$5.47M
-$5.97M
-$6.37M
-$6.56M
Basic earnings per share
-$0.14
-$0.20
-$0.24
-$0.19
-$0.25
-$0.30
-$0.32
-$0.33
Diluted earnings per share
-$0.14
-$0.20
-$0.24
-$0.19
-$0.25
-$0.30
-$0.32
-$0.33
Recent news
Company coverage with links to the original publishers.
Actuate Therapeutics announced that the USPTO issued a Notice of Allowance for its oral tablet formulation of elraglusib, a GSK-3β inhibitor for difficult-to-treat cancers. The oral tablet is designed to enable convenient daily dosing with sustained plasma exposure, potentially enhancing anti-tumor immune response. The company plans to initiate a Phase 1/2 clinical trial in Q1 2027.
Actuate Therapeutics, a clinical-stage biopharmaceutical company, announced the pricing of an underwritten public offering of approximately 30.99 million shares of common stock and 15.49 million warrants at $0.71 per share-warrant set. The offering is expected to raise approximately $11.0 million in gross proceeds, with potential additional proceeds of $7.0 million if warrants are fully exercised. The company plans to use net proceeds for working capital and general corporate purposes.
AbbVie announced that its investigational antibody-drug conjugate Temab-A (telisotuzumab adizutecan) has received two FDA Breakthrough Therapy designations for colorectal cancer and non-small cell lung cancer. The designations were based on data from the M21-404 study, and the company is evaluating Temab-A across multiple advanced solid tumors as part of its expanding oncology pipeline.
Actuate Therapeutics presented clinical data at ASCO 2026 showing that elraglusib combined with chemotherapy regimens (gemcitabine/Abraxane and FOLFIRINOX) demonstrated significant survival improvements in metastatic pancreatic cancer patients, particularly those with wild-type KRAS and TP53 genomics. The drug showed favorable tolerability across both combination settings, with median overall survival improvements ranging from 6-7 months in certain patient subgroups.
Actuate Therapeutics announced that CEO Dan Schmitt will present at the Citizens Life Sciences Conference on March 10, 2026. The company also plans to expand its clinical pipeline by advancing elraglusib tablet into a Phase 1/2 clinical program for refractory cancers, with the phase 1 portion planned to initiate in the second half of 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.